West Pharmaceutical Services, Inc. · NYSE:WST

West Pharmaceutical Services — Fall Investor Relations Conferences 2015

17 slides from West Pharmaceutical Services's conference presentation, Sep 10, 2015

  1. Slide 1: West Pharmaceutical Services, Inc. Fall Investor Relations Conferences

    1 West Pharmaceutical Services, Inc. Fall Investor Relations Conferences New York, NY September, 2015

  2. Slide 2: Safe harbor statement

    2 Safe harbor statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements i

  3. Slide 3: Who we are

    3 Who we are By your side… Every day, injectable drugs are administered to improve the lives of millions of patients around the world. West works side-by-side with its pharmaceutical, biopharmaceutical, generic and medical device partners to design and manufacture packaging and delivery systems that

  4. Slide 4: An integral part of the healthcare industry

    4 An integral part of the healthcare industry Top 35 injectable biologics rely on West and Daikyo components ~40 Billion components manufactured annually >100 million contract manufactured components & assemblies for pens and auto-injectors annually

  5. Slide 5: West business—at a glance

    5 West business—at a glance 2014 Sales by Category No customer greater than 8% of sales Operations in 20 countries & 27 sites 7,000 Employees 7% 21% 35% 31% 6% 31%  High-Value Packaging  Standard Packaging  Disposable Components  Proprietary Devices  Contract Manufacturing 2014 Sales by Geograp

  6. Slide 6: West's role in delivering medicines to patients

    West’s role in delivering medicines to patients Pharmaceutical Packaging Systems (PPS)  Designed-in primary packaging • Stoppers • Seals • Prefilled solutions  Lab Services  Regulatory Expertise PPS $1.0B PDS $0.4B Pharmaceutical Delivery Systems (PDS)  Proprietary products: • Self-Injection Dev

  7. Slide 7: West business growth

    West business growth 2010 2011 2012 2013 2014 6.1% CAGR $1,104.7 $1,421.4 2010 2011 2012 2013 2014 $0.95 $1.75 2010 2011 2012 2013 2014 + 260 BPS 7.6% 10.2% Sales 2010 – 2014 ($ millions) Diluted EPS 2010 – 2014 ROIC 2010 – 2014 7 6.1% CAGR Strong sales & EPS growth and ROIC expansion 10.5% CAGR +26

  8. Slide 8: Product sales & margin growth 2010-2014

    8 Circles reflect relative size of 2014 sales--PPS Sales: PDS Sales: Disposable Components Standard Packaging High-Value Products -5% 0% 5% 10% 15% 20% 25% 0% 30% 60% Category Gross Margin % Proprietary Contract Manufacturing 2014 GM 31.5% 5-Yr Sales CAGR 6.4% Product sales & margin growth 2010-2014

  9. Slide 9: Market trends support growth opportunities

    9 Market trends support growth opportunities West believes it is well positioned to offer packaging & delivery options to address customer needs Increase in Generics & Biosimilars Biologic Product Pipelines Demand for Alternative Treatment & Delivery Options Aging Population & Developing Economies I

  10. Slide 10: Our growth initiatives

    10 Our growth initiatives  Increase high-value product utilization  Operational Excellence • HVP manufacturing expansion across geographies to build capacity • Quality Culture Initiative  Increase adoption of Daikyo Crystal Zenith® systems & SmartDose® injector  Maximize contract manufacturing c

  11. Slide 11: High-value product strategy

    11 High-value product strategy Coated Washed Sterilized Camera Inspected Top Quality West can deliver increasing levels of quality to suit particular customer and drug requirements

  12. Slide 12: Geographic expansion

    12 Geographic expansion  Initiated Waterford, Ireland expansion • Phase 1 commenced in 7/15 • Expected to be operational by 2018  Expanded Kinston site to include high-value processing for components • Dual sourcing/risk mitigation • Commercial orders Q3  Adding high-value product capacity in Sin

  13. Slide 13: Proprietary product strategy

    13 Ease of use, compliance, accuracy, human factors Safety, efficacy, dosage, frequency Synergy, functionality, manufacture, preparation Stability, quality, materials, filling Proprietary product strategy Patient Dru g D e li v e ry D e v ic e Primary Container Integrated Drug Delivery System

  14. Slide 14: CZ and SmartDose uptake

    14 CZ and SmartDose uptake  SmartDose® Electronic Wearable Injector • Opportunity for a growing number of large-volume biologics • Preference for at-home use • 8 active development projects (including Phase III) • Increased manufacturing capacity in Arizona  Daikyo Crystal Zenith® Vials and Syring

  15. Slide 15: Contract Manufacturing supports customers

    15 Contract Manufacturing supports customers  Achieving our goals for growth in drug delivery & diagnostics • Auto-Injector growth • Rapid growth in alternative injectable delivery systems and point-of-care diagnostics  Key partner in the growing diabetes market  Completion of quality control ini

  16. Slide 16: Take-away messages

    16  Key partner to pharmaceutical, biotech, generic and medical device customers  “Sticky” core business – significant barriers to entry  Strong competitive position • Diversified customer base • Maturing proprietary technology pipeline • Global footprint with strong position in fast growing Asia

  17. Slide 17: West Pharmaceutical Services, Inc.

    17 West Pharmaceutical Services, Inc.

West Pharmaceutical Services — Fall Investor Relations Conferences 2015 on 6ix